company background image
DBTX

Decibel Therapeutics NasdaqGS:DBTX Stock Report

Last Price

US$3.34

Market Cap

US$82.4m

7D

29.0%

1Y

-22.7%

Updated

29 Jan, 2023

Data

Company Financials +

Decibel Therapeutics, Inc.

NasdaqGS:DBTX Stock Report

Mkt Cap: US$82.4m

DBTX Stock Overview

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders.

DBTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Decibel Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Decibel Therapeutics
Historical stock prices
Current Share PriceUS$3.34
52 Week HighUS$5.78
52 Week LowUS$1.61
Beta0
1 Month Change62.93%
3 Month Change-9.73%
1 Year Change-22.69%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.48%

Recent News & Updates

Recent updates

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01
We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Shareholder Returns

DBTXUS BiotechsUS Market
7D29.0%0.8%2.8%
1Y-22.7%7.1%-9.2%

Return vs Industry: DBTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: DBTX underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is DBTX's price volatile compared to industry and market?
DBTX volatility
DBTX Average Weekly Movement13.5%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: DBTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: DBTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201362Laurence Reidhttps://www.decibeltx.com

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company’s lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.

Decibel Therapeutics, Inc. Fundamentals Summary

How do Decibel Therapeutics's earnings and revenue compare to its market cap?
DBTX fundamental statistics
Market CapUS$82.42m
Earnings (TTM)-US$59.97m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DBTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$59.97m
Earnings-US$59.97m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DBTX perform over the long term?

See historical performance and comparison